# Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00951444** · PHASE2 · WITHDRAWN · sponsor: **Alliance for Clinical Trials in Oncology**

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** dalotuzumab
- **DRUG:** carboplatin
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00951444
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was not activated.
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951444, "Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00951444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*